Celcuity Inc. (NASDAQ:CELC) Short Interest Up 11.4% in September

Celcuity Inc. (NASDAQ:CELC) saw a large growth in short interest in the month of September. As of September 15th, there was short interest totalling 2,550,000 shares, a growth of 11.4% from the August 31st total of 2,290,000 shares. Based on an average daily volume of 416,400 shares, the short-interest ratio is presently 6.1 days.

Hedge Funds Weigh In On Celcuity

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quest Partners LLC lifted its holdings in shares of Celcuity by 31.3% during the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock worth $95,000 after acquiring an additional 1,379 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in Celcuity by 78.5% during the first quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock worth $193,000 after purchasing an additional 3,930 shares during the last quarter. Pale Fire Capital SE boosted its holdings in shares of Celcuity by 38.4% in the 4th quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock worth $210,000 after purchasing an additional 4,000 shares in the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of Celcuity by 9.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after purchasing an additional 1,500 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in shares of Celcuity by 7.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock valued at $361,000 after purchasing an additional 1,600 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Stock Performance

Shares of Celcuity stock traded down $0.39 during trading hours on Tuesday, reaching $14.52. The company had a trading volume of 54,015 shares, compared to its average volume of 289,848. The company has a debt-to-equity ratio of 0.54, a current ratio of 14.95 and a quick ratio of 14.95. Celcuity has a one year low of $8.39 and a one year high of $22.19. The firm has a market cap of $509.67 million, a PE ratio of -5.19 and a beta of 0.76. The business has a fifty day simple moving average of $16.27 and a 200 day simple moving average of $16.75.

Celcuity (NASDAQ:CELC) last posted its earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same period in the previous year, the firm earned ($0.66) EPS. On average, analysts anticipate that Celcuity will post -2.54 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CELC has been the subject of several research reports. Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Celcuity in a research report on Thursday, August 15th. Lifesci Capital began coverage on shares of Celcuity in a report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target on the stock. Stifel Nicolaus reduced their price objective on Celcuity from $40.00 to $39.00 and set a “buy” rating for the company in a report on Thursday, August 15th. HC Wainwright restated a “buy” rating and issued a $27.00 target price on shares of Celcuity in a research note on Thursday, August 15th. Finally, Leerink Partnrs upgraded Celcuity to a “strong-buy” rating in a research note on Monday, July 22nd. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Celcuity has an average rating of “Buy” and a consensus price target of $28.67.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.